-
Je něco špatně v tomto záznamu ?
Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres
R. Jorda, K. Paruch, V. Krystof,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- antitumorózní látky chemie farmakologie MeSH
- cyklin-dependentní kinasy antagonisté a inhibitory MeSH
- heterocyklické sloučeniny chemie farmakologie MeSH
- inhibitory proteinkinas chemie farmakologie MeSH
- lidé MeSH
- nádory farmakoterapie enzymologie MeSH
- puriny chemie farmakologie MeSH
- racionální návrh léčiv MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000829
- 003
- CZ-PrNML
- 005
- 20130109113159.0
- 007
- ta
- 008
- 130108s2012 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/138161212800672804 $2 doi
- 035 __
- $a (PubMed)22571665
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Palacky University, Slechtitelu 11, 78371, Olomouc, Czech Republic.
- 245 10
- $a Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres / $c R. Jorda, K. Paruch, V. Krystof,
- 520 9_
- $a Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
- 650 _2
- $a antitumorózní látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a cyklin-dependentní kinasy $x antagonisté a inhibitory $7 D018844
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a heterocyklické sloučeniny $x chemie $x farmakologie $7 D006571
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x farmakoterapie $x enzymologie $7 D009369
- 650 _2
- $a inhibitory proteinkinas $x chemie $x farmakologie $7 D047428
- 650 _2
- $a puriny $x chemie $x farmakologie $7 D011687
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Paruch, Kamil
- 700 1_
- $a Krystof, Vladimír
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 18, č. 20 (2012), s. 2974-80
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22571665 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20130109113304 $b ABA008
- 999 __
- $a ok $b bmc $g 963611 $s 798993
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 18 $c 20 $d 2974-80 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20130108